Epigen Inc. has arranged with Immunotech Corp. to incorporatean Epigen blood test for a cancer antigen into Immunotech'stest kits.

Epigen of Wellesley, Mass., will pay Immunotech on a time andmaterial basis to incorporate the cancer test into kits for testingin clinical trials. The trials are expected to start in the secondhalf of the year.

Epigen (AMEX:EPN.EC) has identified a glycoprotein called HCantigen that is present on the cells of nearly all cancers, but noton healthy tissues. The substance can be followed to reveal thebody burden of cancer, whether the disease remains inremission, or if it is recurring.

Boston-based Immunotech markets diagnostic kits to detectthyroid and steroid hormones, drugs and drugs of abuse.

(c) 1997 American Health Consultants. All rights reserved.